Latest news

Spotlight on our syngeneic MCA205 tumor model: A reliable tool to investigate novel therapy combination

06 / 01 / 2021

Spotlight on our syngeneic MCA205 tumor model: A reliable tool to investigate novel therapy combination

Using a syngeneic MCA205 sarcoma tumor model – widely used for the evaluation of innovative cancer immunotherapies – we investigated the anti-tumor activity of several combination therapies. This model is known to be responsive to PD1/PDL1 axis blockade but only partially to anti-CTLA4 antibody. Interestingly, while an additive benefit of anti-PD1 and anti-PDL1 is observed, a clear synergistic effect is achieved upon combination of either anti-PD1 or anti-PDL1 with anti-CTLA4, with a full tumor rejection in all treated animals.

 

A syngeneic orthotopic glioblastoma mouse model

04 / 22 / 2021

A syngeneic orthotopic glioblastoma mouse model

Spotlight on the immunomodulatory and anti-tumor activities of Temozolomide

Glioblastoma
(GBM) is the most common malignant adult brain tumor. Despite the multimodality of treatment strategies including surgery, radiotherapy and chemotherapy, with a standard of care being temozolomide (TMZ) in combination with radiotherapy, the prognosis of GBM patients is still dismal, and the need to develop and assess novel combinatorial strategies remains critical.

Explicyte and Institut Bergonié associate in a clinical trial report publication

02 / 25 / 2021

Explicyte and Institut Bergonié associate in a clinical trial report publication

Digital pathology for tumor immune infiltrate analysis and patient selection
To assess whether or not the tumor immune contexture was predictive of response to the Avelumab-Regorafenib combination regimen, Explicyte developed and ran, on baseline FFPE samples, a multiplexed immunohistofluorescence panel consisting of CD8, PD1, PDL1, CD163, IDO1, and PanKeratin markers, in addition to Dapi (Discovery XT, Roche Diagnostics).

Explicyte is proud to be a certified Nanostring partner - Let’s start the Digital Spatial Profiling revolution together!

12 / 10 / 2020

Explicyte is proud to be a certified Nanostring partner - Let’s start the Digital Spatial Profiling revolution together!

It therefore becomes primordial to benefit from a technological platform that allows to deal with the tumor biology complexity/heterogeneity and get specific investigations in compartments of interest (e.g. tumor vs stroma). Thanks to the GeoMx platform (Nanostring Inc.), which combines the spatial resolution of immunohistofluorescence with the high-plex gene/protein expression analysis, the Digital Spatial Profiling (DSP) revolution has started.

A syngeneic renal cancer mouse model for the discovery of novel immuno-oncology therapies

11 / 18 / 2020

A syngeneic renal cancer mouse model for the discovery of novel immuno-oncology therapies

We have fully set up and characterized a syngeneic Renca renal mouse model recapitulating most of the human RCC condition features. Indeed, our model displays an enriched tumor microvascular environment and relatively low immune infiltration - nevertheless constituted of a strong Myeloid-Derived Suppressor Cells (MDSCs) proportion.